Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: A retrospective study in newly diagnosed elderly myeloma

European Journal of Haematology

Volumn 85, Issue 3, 2010, Pages 200-208

  Gay, Francesca ^a,b   Vincent Rajkumar, S S ^a   Falco, Patrizia ^c   Kumar, Shaji ^a   Dispenzieri, Angela ^a   Petrucci, Maria Teresa ^d   Gertz, Morie A ^a   Boccadoro, Mario ^b   Keith Stewart, A A ^e   Palumbo, Antonio ^b  

^a Mayo Clinic College of Medicine   (United States)

^b UNIVERSITY OF TURIN   (Italy)

^c Ospedale di Ivrea   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e MAYO CLINIC   (United States)

Author keywords

lenalidomide; melphalan; myeloma; steroids

Indexed keywords

ACETYLSALICYLIC ACID; DEXAMETHASONE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; LENALIDOMIDE; MELPHALAN; PREDNISONE; ANTINEOPLASTIC AGENT; THALIDOMIDE;

AGED; ANEMIA; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HOSPITAL; HUMAN; INFECTION; LOW DRUG DOSE; LUNG EMBOLISM; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPHYLAXIS; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; MULTIPLE MYELOMA; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; FEMALE; HUMANS; MALE; MELPHALAN; MULTIPLE MYELOMA; PREDNISONE; RETROSPECTIVE STUDIES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 77955816305     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01469.x     Document Type: Article

References (22)

1. Rajkumar SV, Kyle R. Plasma cell disorders. In : Goldman L, Ausiello D, eds. Cecil Textbook of Medicine, 23rd edn.
2. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004 351 : 1860 73.
3. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002 100 : 3063 7.
4. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of multiple myeloma cells to conventional therapy. Blood 2000 96 : 2943 50.
5. Weber DM, Chen C, Niesvizky R, et al. Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007 357 : 2133 42.
6. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007 357 : 2123 32.
7. Zonder JA, Crowley J, Hussein MA, Bolejack V, Moore DF, Whittenberger BF, Abidi MH, Durie BG, Barlogie B. Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of Newly-Diagnosed Multiple Myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG trial S0232. ASH Annu Meet Abstr 2007 110 : 77.
8. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010 11 : 29 37.
9. Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA Italian multiple myeloma network. J Clin Oncol 2007 25 : 4459 65.
10. Palumbo A, Falco P, Falcone A, et al. Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results. Clin Lymphoma Myeloma 2009 9 : 145 50.
11. Lacy MQ, Gertz MA, Dispenzieri AA, et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 2007 82 : 1179 84.
12. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009 23 : 3 9.
13. National Cancer Institute: Common Terminology Criteria for Adverse Events, v3.0, (CTCAE) http://ctep.cancer.gov/protocolDevelopment/electronic- applications/ctc.htm#ctc-v3.0.
14. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958 53 : 457 81.
15. Facon T, Mary J-Y, Pegourie B, et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 2006 107 : 1292 8.
16. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007 370 : 1209 18.
17. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006 367 : 825 31.
18. Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 0101 trial. J Clin Oncol 2009 27 : 3664 70.
19. Waage A, Gimsing P, Juliusson G, Turesson I, Fayers P. Melphalan-prednisone-thalidomide to newly diagnosed patients with multiple myeloma: a placebo controlled randomised phase 3 trial. ASH Annu Meet Abstr 2007 110 : 78.
20. Wijermans P, Schaafsma M, van Norden Y, et al. Melphalan + prednisone versus melphalan + prednisone + thalidomide in induction therapy for multiple myeloma in elderly patients: final analysis of the Dutch Cooperative Group HOVON 49 Study. Blood (ASH Annu Meet Abstr) 2008 112 : 649.
21. Ludwig H, Hajek R, Tothova E, et al. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 2009 113 : 3435 42.
22. Palumbo A, Dimopoulos MA, Delforge M, et al. A phase III study to determine the efficacy and safety of lenalidomide in combination with melphalan and prednisone (MPR) in elderly patients with newly diagnosed multiple myeloma. Blood (ASH Annual Meeting Abstract) 2009 abstract 613.